Appili Therapeutics Inc. (APLI.H)
TSXV
Closed
Oct 30, 2026
Day's Range
0.0050052 wk Range
0.00500Profile - APLI.H - Appili Therapeutics Inc.
Profile
Mic Code
XTSX
Sector
Healthcare
Industry
Biotechnology
Employees
7
Appili Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing treatments for infectious diseases and medical countermeasures. Its current portfolio includes LIKMEZ, a liquid oral formulation of metronidazole designed for anaerobic bacterial and protozoal infections, as well as ATI-1801, a topical paromomycin formulation under development for cutaneous leishmaniasis. The company is also advancing ATI-1701, a live-attenuated vaccine candidate, and working with Vitalex Biosciences on VXV-01, a dual-antigen vaccine program targeting invasive Candida infections. Based in Halifax, Nova Scotia, Appili Therapeutics concentrates on anti-infective products that address unmet clinical needs in the United States and Canada.
Profile Details
Type
Common Stock
Ceo
Dr. Donald D. Cilla Jr., M.B.A., Pharmd
Address
1344 Summer Street
City
Halifax
State
NS
Zip
B3H 0A8
Country
Canada
Phone
902-442-4655
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
